Claim Uncertain
REGENXBIO expects to complete enrollment of approximately 30 patients a...
REGENXBIO: REGENXBIO expects to complete enrollment of approximately 30 patients aged 1+ in the U.S.... Published Aug 7, 2025. Status: Uncertain. No credible e...
REGENXBIO expects to complete enrollment of approximately 30 patients aged 1+ in the U.S. and Canada for the AFFINITY DUCHENNE® pivotal trial of RGX-202 for Duchenne muscular dystrophy.
FactTracker assessment
No credible evidence shows that REGENXBIO completed enrollment of ~30 patients in the U.S. and Canada for the...
Verification rule: Event occurs: REGENXBIO expects to complete enrollment of approximately 30 patients aged 1+ in the U.S. and Canada for the AFFINITY DUCHENNE® pivotal trial of RGX-202 for Duchenne muscular dystrophy.; window 2025-08-07 to 2025-10-31
Original source: ir.regenxbio.com